We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Teva CEO Kåre Schultz has spent nearly two years working through major issues at the generics giant. Now, he’ll need to replace his CFO, as Michael McClellan is stepping down.